版本:
中国

BRIEF-Coherus Biosciences receives CRL from FDA for biologics license application for CHS-1701

June 12 Coherus Biosciences Inc

* Coherus Biosciences receives complete response letter from fda for its biologics license application for chs-1701 (pegfilgrastim biosimilar candidate)

* Coherus will work with fda to address information requests

* Coherus Biosciences -crl primarily focused on fda request for a reanalysis of a subset of subject samples with a revised immunogenicity assay

* Coherus Biosciences inc - fda did not request a clinical study to be performed in oncology patients

* Coherus Biosciences inc says crl also focused on fda requests for certain additional manufacturing related process information

* Coherus Biosciences-‍crl does not indicate additional process qualification lots would be required or raise concerns on gmp status of chs-1701 bulk manufacturing Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐